MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis

Akkiz "MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population" Cancer Epidemiol. (2010) 10.1016/j.canep.2010.04.008

[3]

Alazzouzi "Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells" J. Med. Genet. (2007) 10.1136/jmg.2006.042572

[4]

Alhopuro "The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck" J. Med. Genet. (2005) 10.1136/jmg.2005.031260

[5]

Arva "A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells" J. Biol. Chem. (2005) 10.1074/jbc.m505203200

[6]

Ashton "Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer" Gynecol. Oncol. (2009) 10.1016/j.ygyno.2008.12.036

[7]

Asomaning "MDM2 promoter polymorphism and pancreatic cancer risk and prognosis" Clin. Cancer Res. (2008) 10.1158/1078-0432.ccr-07-4187

[8]

Boersma "Association of breast cancer outcome with status of p53 and MDM2 SNP309" J. Natl. Cancer Inst. (2006) 10.1093/jnci/djj245

[9]

Bond "A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect" Cancer Res. (2005) 10.1158/0008-5472.can-05-0825

[10]

Bond "A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans" Cell (2004) 10.1016/j.cell.2004.11.022

[11]

Campbell "No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer" Cancer Lett. (2006) 10.1016/j.canlet.2005.09.003

[12]

Capasso "MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness" J. Hum. Genet. (2010) 10.1038/jhg.2010.62

[13]

Chen "Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma" Cancer Res. (2010) 10.1158/0008-5472.can-09-4733

[14]

Chen "Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis" Anal. Bioanal. Chem. (2009) 10.1007/s00216-008-2416-y

[15]

Cho "No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients" Neoplasma (2008)

[16]

Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore

Hui Wan Chua, Daniel Ng, Serena Choo et al.

BMC Cancer 2010 10.1186/1471-2407-10-88

[17]

Cox "The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies" Cancer Causes Control (2007)

[18]

Meta-analysis in clinical trials

Rebecca DerSimonian, Nan Laird

Controlled Clinical Trials 1986 10.1016/0197-2456(86)90046-2

[19]

Dharel "MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C" Clin. Cancer Res. (2006) 10.1158/1078-0432.ccr-06-0111

[20]

Bias in meta-analysis detected by a simple, graphical test

Matthias Egger, George Davey Smith, Martin Schneider et al.

BMJ 1997 10.1136/bmj.315.7109.629

[21]

El Hallani "No association of MDM2 SNP309 with risk of glioblastoma and prognosis" J. Neurooncol. (2007) 10.1007/s11060-007-9416-1

[22]

Ellis "MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility" Blood (2008) 10.1182/blood-2007-11-126508

[23]

Ezzikouri "MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population" Cancer Detect. Prev. (2009) 10.1016/j.cdp.2009.01.003

[24]

Freedman "Functions of the MDM2 oncoprotein" Cell. Mol. Life Sci. (1999) 10.1007/s000180050273

[25]

Gangwar "Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population" DNA Cell Biol. (2010) 10.1089/dna.2009.0982

[26]

Grochola "MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation" Pancreas (2010) 10.1097/mpa.0b013e3181b9f105

[27]

Hamid "MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset" Oral Oncol. (2009) 10.1016/j.oraloncology.2008.06.003

[28]

Haupt "Mdm2 promotes the rapid degradation of p53" Nature (1997) 10.1038/387296a0

[29]

Hirata "MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma" Clin. Cancer Res. (2007) 10.1158/1078-0432.ccr-07-0609

[30]

Hirata "Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy" J. Urol. (2009) 10.1016/j.juro.2008.11.093

[31]

Hirschhorn "A comprehensive review of genetic association studies" Genet. Med. (2002) 10.1097/00125817-200203000-00002

[32]

Hong "The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma" Cancer Res. (2005) 10.1158/0008-5472.can-05-1460

[33]

Horikawa "Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder" Oncol. Rep. (2008)

[34]

Hu "MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies" Cancer Epidemiol. Biomarkers Prev. (2007) 10.1158/1055-9965.epi-07-0634

[35]

Hu "Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population" Int. J. Cancer (2006) 10.1002/ijc.21463

[36]

Jun "Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer" Mol. Carcinog (2007) 10.1002/mc.20279

[37]

Kang "Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women" Int. J. Gynecol. Cancer (2009) 10.1111/igc.0b013e3181a130ab

[38]

Khatri "The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme" J. Neurosurg. (2008) 10.3171/jns/2008/109/11/0842

[39]

Kibel "Association between polymorphisms in cell cycle genes and advanced prostate carcinoma" Prostate (2008) 10.1002/pros.20784

[40]

Kinyamu "Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression" Mol. Cell. Biol. (2003) 10.1128/mcb.23.16.5867-5881.2003

[41]

Regulation of p53 stability by Mdm2

Michael H. G. Kubbutat, Stephen N. Jones, Karen H. Vousden

Nature 1997 10.1038/387299a0

[42]

Lang "The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol" Rep (2009)

[43]

Leu "Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population" World J. Gastroenterol. (2009) 10.3748/wjg.15.5592

[44]

MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis

G. Li

Carcinogenesis 2006 10.1093/carcin/bgl047

[45]

Lind "Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer" Int. J. Cancer (2006) 10.1002/ijc.21872

[46]

Liu "Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk" Int. J. Cancer (2008) 10.1002/ijc.23178

[47]

Liu "Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population" Chin. J. Oncol. (2008)

[48]

Ma "Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population" Cancer Lett. (2006) 10.1016/j.canlet.2005.09.019

[49]

Mantel "Statistical aspects of the analysis of data from retrospective studies of disease" J. Natl. Cancer Inst. (1959)

[50]

Marcel "TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis" J. Med. Genet. (2009) 10.1136/jmg.2009.066704

Showing 50 of 91 references

Metrics

2

Citations

91

References

Details

Published: Aug 01, 2011
Vol/Issue: 38(8)
Pages: 341-350
License: View

Authors

Southwest University

China Coal Research Institute; China Coal Research Institute Fushun Branch, Shenfu Demonstration Zone

Changchun University of Science and Technology

Y

Yang Yu

Department of Biological Sciences, Purdue University, West Lafayette, IN 47907;

Cite This Article

Xiaoman Wo, Dong Han, Haiming Sun, et al. (2011). MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis. Journal of Genetics and Genomics, 38(8), 341-350. https://doi.org/10.1016/j.jgg.2011.07.005

MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis

You May Also Like